MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
183.81
+2.26
+1.24%
Opening 14:00 03/16 EDT
OPEN
182.76
PREV CLOSE
181.55
HIGH
184.62
LOW
181.88
VOLUME
323.62K
TURNOVER
--
52 WEEK HIGH
202.41
52 WEEK LOW
110.04
MARKET CAP
26.98B
P/E (TTM)
20.91
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BIIB last week (0309-0313)?
Weekly Report · 8h ago
Does New Once-Yearly SMA Data And Phase 3 Plan Change The Bull Case For Biogen (BIIB)?
Simply Wall St · 2d ago
Assessing Biogen (BIIB) Valuation After Recent Shareholder Return Momentum
Simply Wall St · 3d ago
Jefferies Reaffirms Their Buy Rating on Biogen (BIIB)
TipRanks · 4d ago
Oppenheimer Reaffirms Their Buy Rating on Biogen (BIIB)
TipRanks · 4d ago
Analysts Conflicted on These Healthcare Names: Valneva (VALN), Biogen (BIIB) and Ginkgo Bioworks Holdings (DNA)
TipRanks · 4d ago
Biogen Announces Upcoming Departure of Chief Legal Officer
TipRanks · 4d ago
BIOGEN - SUSAN H. ALEXANDER, CHIEF LEGAL OFFICER, TO DEPART EFFECTIVE END OF MAY 2026 - SEC FILING
Reuters · 4d ago
More
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.